<![CDATA[Systematic review of studies on HPV type-replacement after generalized vaccination]]>

Dr. David Mesher presented results of by far the largest meta-analysis on type-replacement following HPV vaccination.

The study initially identified 4219 unique reports comparing type-specific HPV prevalence before and after the introduction of the HPV vaccination program [1]. Out of these, nine studies reported type-specific HPV prevalence pre- and post-vaccination in 16 to 19 year-old and in 20 to 24 year-old females. The meta-analysis included studies conducted in countries using either the bivalent HPV16/18 vaccine (three studies) or the quadrivalent HPV6/11/16/18 vaccine (six studies). The populations comprised three studies conducted among women attending for chlamydia screening (25,151 samples), two studies conducted in women attending for cervical screening (6,575 samples), two population-based surveys (4,124 samples) and two in women attending a primary care clinic (973 samples). Altogether, type-specific HPV prevalence data was available from 36,823 study participants.

For the non-vaccine HPV types the combined (both vaccines included) pre- vs. post-vaccination comparisons revealed evidence of a reduced prevalence for HPV31 in both age-categories, but little evidence for reductions in HPV33 or HPV45. There was some evidence of an increased prevalence for HPV39 (figure 1), and to a lesser extent for HPV 52, 58 and 73 although results were inconsistent between age-groups.

In conclusion, the meta-analysis verified vaccine induced cross-protection against HPV31 for both the bivalent and the quadrivalent HPV vaccine. It did not provide clear-cut evidence of HPV type-replacement as data was unclear about whether changes in other non-vaccine types are due to changes in study populations or possible unmasking of non-vaccine types with low viral load. The effect of differential vaccination coverage as a source of heterogeneity could not be assessed due to the relatively small number of studies included in the meta-analysis.

The meta-analysis verified vaccine induced cross-protecion against HPV31 for both the bivalent and quadrivalent HPV vaccine. It did not provide clear-cut evidence of HPV type-replacement

Prevalence ratios were not calculated if there was evidence of heterogeneity of data (I² value ≥25%). For HPV 39, borderline increases in prevalence were observed after the vaccination campaign. Adapted from [1].

Figure 1.

Prevalence ratios and 95% CI for HPV35, HPV39 and HPV51 comparing pre- and post-vaccination periods in young women.

References
1. Mesher D, Soldan K, Lehtinent, et al. Population- Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis. 2016 Oct; 22(10): 1732–1740.

]]>

David Mesher, MD
Public Health England
London, England
d.mesher@phe.gov.uk

]]>

Related articles

All articles

HPV Transmission Not Involving Penetrative Sex

Can we use one dose of HPV vaccine to ensure long term protection?

Cytology and HPV testing for anal HSIL screening

Trends in the incidence of vulvar and vaginal cancers

Login